Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.

导出 OA

翻译打印收藏纠错

作者： Rami S,Komrokji ^[1] ; Avani M,Singh ^[2] ; Najla Al,Ali ^[3] ; Onyee,Chan ^[3] ; Eric,Padron ^[3] ; Kendra,Sweet ^[3] ; Andrew,Kuykendall ^[3] ; Jeffrey E,Lancet ^[3] ; David A,Sallman ^[3]

作者单位： Department of Malignant Hematology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA. rami.komrokji@moffitt.org. ^[1] Department of Hematology/Oncology, University of South Florida &amp; Moffitt Cancer Center, Tampa, FL, USA. ^[2] Department of Malignant Hematology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA. ^[3]

主题词人类(Humans);磺胺类(Sulfonamides);骨髓增生异常综合征(Myelodysplastic Syndromes);白血病, 髓样, 急性(Leukemia, Myeloid, Acute)

DOI 10.1038/s41408-022-00744-z

PMID 36329025

发布时间 2022-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交